Energy One’s acquisition of CQ Energy should create growth opportunities in renewable energy, but it also brings notable risks.

Quarterly reports of Rightcrowd, IntelliHR and Volpara update us on free cash flow and annualised recurring revenue growth…

By my reckoning this company is trading on about 15 times earnings and yielding at least 4% in dividends. And growth is likely, albeit not certain.

The Genetic Signatures (ASX:GSS) share price has dropped almost 10% despite reporting record receipts from customers.

The BeforePay share price is at 29% below the IPO price, but what does BeforePay the company actually do?

People generally prefer to believe what is comforting over the unpleasant truth, and investors can use that to profit.

I think the Australian Clinical Labs (ASX: ACL) is likely to fall in the short term as the Morrison government moves to restrict PCR testing.

The Ebos Group (ASX: EBO) retail equity offer has me considering if I want to increase my position, or arbitrage the discount for a profit.

The second half of 2021 saw my portfolio take a hit, as growth stocks entered a downturn…

This ASX listed med-tech company has an enterprise value of less than $200m, but has expanded its customer base significantly, as a result of the pandemic.

As we see out the end of 2021, all signs point to a bumpy start to 2022. Here’s how I’m thinking about inflation, Omicron, and the end of 2021.

Australian Clinical Labs (ASX:ACL) makes millions in profits from covid testing, and the Omicron variant has seen covid testing increase once more…

The PTB Group (ASX:PTB) share price has recovered strongly from the pandemic, but its growth plans are far from over.

Alcidion (ASX:ALC) is bolstering its product offering with its acquisition of Silverlink Software. What does it mean for shareholders?

The new Omicron variant is not causing me to panic, but I am tweaking my portfolio a little to prepare for (likely) harder times ahead.

The Alcidion share price is up around 10% after it confirmed its largest ever contract win, worth at least $23 million.

Claude Walker, Matt Joass, Andrew Page, and Kevin Fung discuss Nanosonics stock and the impact of omicron on investors.

Pro Medicus (ASX:PME) revealed significant progress with its AI Accelerator at the PME 2021 AGM and a strong contract pipeline.

Owen Raszkiewicz, Anirban Mahanti, and Claude Walker sit down to chat Pro Medicus (ASX:PME), Damstra (ASX:DTC), Tesla and Peloton stocks.

We’ve listed the company name, time of the meeting, and the link for you to join or register, below. Ask a question!